<DOC>
	<DOC>NCT00595686</DOC>
	<brief_summary>Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.</brief_summary>
	<brief_title>Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>&gt;18 years old Karnofsky performance status &gt; 60 confirmed hematological malignancy refractory to available therapy or for which no therapy is available adequate hepatic, renal and hematological function CNS malignancy at risk for prolonged QT interval significant GI/liver disease other serious concurrent illness or medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hematologic Malignancies Hsp90 Hematologic Malignancy</keyword>
</DOC>